Genmab A/S (GMAB)
| Market Cap | 19.98B +25.7% |
| Revenue (ttm) | 4.13B +22.3% |
| Net Income | 788.00M -37.9% |
| EPS | 1.27 -36.8% |
| Shares Out | 59.70M |
| PE Ratio | 25.36 |
| Forward PE | 20.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,518,709 |
| Open | 33.78 |
| Previous Close | 34.10 |
| Day's Range | 33.12 - 33.93 |
| 52-Week Range | 23.62 - 35.43 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 38.84 (+16.88%) |
| Earnings Date | Aug 6, 2026 |
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price target is $38.84, which is an increase of 16.88% from the latest price.
News
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor con...
Genmab Slides: Investor presentation
Genmab has posted slides in relation to its latest quarterly earnings report, which was published on August 22, 2026.
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increa...
Genmab Earnings Call Transcript: Q2 2026
Revenue grew 25% year-over-year, driven by strong sales of EPKINLY and DARZALEX, with adjusted operating profit up 18%. Multiple late-stage data readouts are expected in Q4 2026 and early 2027, supporting a raised full-year revenue outlook and continued investment in pipeline expansion.
Genmab Quarterly report: Q2 2026
Genmab has published its Q2 2026 quarterly earnings report on August 6, 2026.
Genmab Slides: Q2 2026
Genmab has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 stu...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenali...
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets ...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-l...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to em...
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE® FL-1 trial, evaluating epcoritamab, a subcut...
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab...
Genmab Earnings Call Transcript: Q1 2026
Q1 2026 saw 25% revenue growth and 23% operating profit growth, led by strong EPKINLY and TIVDAK sales. Rina-S phase III enrollment finished early, supporting accelerated filings, while guidance for 14% revenue growth and substantial profitability in 2026 was reaffirmed.
Genmab Quarterly report: Q1 2026
Genmab has published its Q1 2026 quarterly earnings report on May 7, 2026.
Genmab Earnings release: Q1 2026
Genmab released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Genmab Slides: Q1 2026
Genmab has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Genmab Announces Financial Results for the First Quarter of 2026
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA appro...
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with ...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, top...